Roth starts Intellipharmaceutics at buy

Roth Capital Partners has initiated coverage of Intellipharmaceutics (NASDAQ:IPCI; TSX:I) with a “buy” rating and 12-month price target of $5.25, saying the emerging generics company could launch four new products in the coming 12-to-18 months. “We believe that this momentum could unlock value for this under covered stock,” writes analyst Scott Henry. The stock closed [...]

Intellipharmaceutics hires Doll to commercialize drugs

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has retained Doll Consulting and its principal, David Doll, to assist the company with the commercialization of products in its controlled-release generic drug and NDA portfolios. “We now have four products filed with the FDA for the purpose of obtaining regulatory approval in the U.S. – ANDA’s for Focalin XR, Effexor [...]

Intellipharmaceutics CEO moulded at Biovail U

Fifteen years ago, Dr. Isa Odidi performed magic as CSO of Biovail (NYSE:BVF; TSX:BVF), developing several blockbuster generics, including hard-to-manufacture copies of Bayer’s Adalat CC, Pfizer’s Procardia XL and Novartis’ Voltaren XR. “We have the same style here at Intellipharmaceutics (NASDAQ:IPCI; TSX:I) as we had at Biovail,” Dr. Odidi says in an exclusive interview with [...]

Intellipharmaceutics advances abuse-deterrent oxycodone

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has taken delivery of and fully qualified its primary manufacturing equipment for the manufacture of oxycodone CR, an abuse-deterrent formulation of controlled-release oxycodone hydrochloride. The company also said it has begun making clinical batches of the drug for Phase 1 studies and to establish a clinical program in cooperation with the [...]

FDA accepts Intellipharmaceutics ANDA

The FDA has accepted an abbreviated new drug application from Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) for a generic version of the antidepressant Effexor XR. “This product was entirely developed and filed using our in-house laboratory, manufacturing and regulatory resources,” CEO Dr. Isa Odidi said in a statement.  “The acceptance of this filing also fulfills one of [...]